No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks
HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target
Express News | Zura Bio Launches Global Phase 2 Tibusure Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Leerink Partners Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $12
Zura Bio (ZURA) Receives a Buy From Piper Sandler